📊 HOOK Key Takeaways
Is HOOKIPA Pharma Inc. (HOOK) a Good Investment?
HOOKIPA exhibits severe operating losses of $15.4M against minimal $2.0M revenue, indicating unsustainable economics and rapid cash depletion despite strong cash reserves. While 118% revenue growth is encouraging, the company's viability depends entirely on successful pharmaceutical development with unclear path to profitability.
HOOKIPA exhibits severe operating losses and deeply negative margins with only $2M in revenue, indicating an early-stage, non-profitable profile. Liquidity is solid (high cash, low debt), but the cash balance appears modest relative to the loss run-rate, implying reliance on external financing unless revenue scales meaningfully. Without clear evidence of sustained operating improvement or commercial-scale revenue, fundamentals skew negative.
Why Buy HOOKIPA Pharma Inc. Stock? HOOK Key Strengths
- Revenue growth of 118.3% YoY demonstrates market traction and adoption
- Strong liquidity position with $40.3M cash reserves and 3.61x current ratio provides 2-3 year operational runway
- Minimal debt burden (0.03x D/E ratio) reduces financial distress risk and refinancing concerns
- Strong liquidity (current/quick 3.61x)
- Low leverage (Debt/Equity 0.03x)
- YoY revenue growth >100% and improving EPS loss
HOOK Stock Risks: HOOKIPA Pharma Inc. Investment Risks
- Severe cash burn with $15.4M net loss against $2.0M revenue creates unsustainable operating model
- Operating margin of -891.9% reveals inability to generate positive returns from core operations at any scale
- Pharma development dependency creates binary outcomes; failure of pipeline candidates could render company insolvent despite cash reserves
- Large, persistent operating losses and negative margins
- Potentially short cash runway; reliance on dilutive financing/partner funding
- Small, concentrated collaboration revenue with execution and milestone timing risk
Key Metrics to Watch
- Quarterly cash burn rate and estimated months of runway
- Clinical trial progression and regulatory milestone achievements
- Operating cash flow inflection point and path to positive unit economics
- Cash runway (cash vs quarterly burn)
- Collaboration/milestone revenue trajectory
HOOKIPA Pharma Inc. (HOOK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 1.6% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.61x current ratio provides a solid financial cushion.
HOOK Profit Margin, ROE & Profitability Analysis
HOOK vs Healthcare Sector: How HOOKIPA Pharma Inc. Compares
How HOOKIPA Pharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HOOKIPA Pharma Inc. Stock Overvalued? HOOK Valuation Analysis 2026
Based on fundamental analysis, HOOKIPA Pharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HOOKIPA Pharma Inc. Balance Sheet: HOOK Debt, Cash & Liquidity
HOOK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: HOOKIPA Pharma Inc.'s revenue has grown significantly by 124% over the 5-year period, indicating strong business expansion. The most recent EPS of $-9.91 indicates the company is currently unprofitable.
HOOK Revenue Growth, EPS Growth & YoY Performance
HOOK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $2.0M | $14.4M | $1.14 |
| Q3 2024 | $4.7M | -$13.8M | $-1.10 |
| Q2 2024 | $1.3M | -$4.7M | $-0.38 |
| Q1 2024 | $3.2M | $14.4M | $0.11 |
| Q3 2023 | $2.2M | -$16.4M | $-0.17 |
| Q2 2023 | $2.7M | -$16.4M | $-0.22 |
| Q1 2023 | $1.4M | -$18.0M | $-0.27 |
| Q3 2022 | $2.2M | -$16.4M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HOOKIPA Pharma Inc. Dividends, Buybacks & Capital Allocation
HOOK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for HOOKIPA Pharma Inc. (CIK: 0001760542)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HOOK
What is the AI rating for HOOK?
HOOKIPA Pharma Inc. (HOOK) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 56% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HOOK's key strengths?
Claude: Revenue growth of 118.3% YoY demonstrates market traction and adoption. Strong liquidity position with $40.3M cash reserves and 3.61x current ratio provides 2-3 year operational runway. ChatGPT: Strong liquidity (current/quick 3.61x). Low leverage (Debt/Equity 0.03x).
What are the risks of investing in HOOK?
Claude: Severe cash burn with $15.4M net loss against $2.0M revenue creates unsustainable operating model. Operating margin of -891.9% reveals inability to generate positive returns from core operations at any scale. ChatGPT: Large, persistent operating losses and negative margins. Potentially short cash runway; reliance on dilutive financing/partner funding.
What is HOOK's revenue and growth?
HOOKIPA Pharma Inc. reported revenue of $2.0M.
Does HOOK pay dividends?
HOOKIPA Pharma Inc. does not currently pay dividends.
Where can I find HOOK SEC filings?
Official SEC filings for HOOKIPA Pharma Inc. (CIK: 0001760542) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HOOK's EPS?
HOOKIPA Pharma Inc. has a diluted EPS of $-1.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HOOK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, HOOKIPA Pharma Inc. has a SELL rating with 56% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HOOK stock overvalued or undervalued?
Valuation metrics for HOOK: ROE of -45.3% (sector avg: 15%), net margin of -769.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HOOK stock in 2026?
Our dual AI analysis gives HOOKIPA Pharma Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HOOK's free cash flow?
HOOKIPA Pharma Inc.'s operating cash flow is $52.0K, with capital expenditures of $20.0K. FCF margin is 1.6%.
How does HOOK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -769.8% (avg: 12%), ROE -45.3% (avg: 15%), current ratio 3.61 (avg: 2).